Literature DB >> 25897610

Preparation and Characterization of a Monoclonal Antibody Against the Core Protein VP7 of the 25th Serotype of Bluetongue Virus.

Xiao Wu1, Qi Liu, Jia He, Mingxin Zang, Haixiu Wang, Yijing Li, Lijie Tang.   

Abstract

Bluetongue virus (BTV) is a member of the genus Orbivirus, within the family Reoviridae. The VP7 protein of BTV is used for developing group-specific serological assays. To prepare monoclonal antibody (MAb) against VP7 of the 25th serotype BTV, the RNA S7 encoding VP7 was cloned into prokaryotic expression vectors pET-28a (+) and pGEX-6P-1 to generate recombinant plasmids. The recombinant protein VP7 was expressed in Escherichia coli BL21 (DE3), respectively. The results of SDS-PAGE revealed that the VP7 was expressed and the molecular mass of recombinant fusion protein pET-28a (+)/VP7 and pGEX-6P-1/VP7 was approximately 44 kDa and 64 kDa, respectively. The Western blot analysis indicated that the recombinant VP7 possessed good immunoreactivity. After purification, pET-28a (+)/VP7 was used to immunize BALB/c mice, while pGEX-6P-1/VP7 was used to screen for well-to-well MAb-secreting hybridomas. The hybridoma cell line 3H7 against recombinant VP7 that secreted MAbs was obtained. The isotype of 3H7 was identified as IgG1. The purification of recombinant VP7 protein and the monoclonal antibody will have potential applications on competitive ELISA format for BT-specific serum detection method.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25897610      PMCID: PMC4410280          DOI: 10.1089/mab.2014.0065

Source DB:  PubMed          Journal:  Monoclon Antib Immunodiagn Immunother        ISSN: 2167-9436


  26 in total

1.  Bluetongue virus with mutated genome segment 10 to differentiate infected from vaccinated animals: a genetic DIVA approach.

Authors:  P A van Rijn; S G P van de Water; H G P van Gennip
Journal:  Vaccine       Date:  2013-09-07       Impact factor: 3.641

2.  Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.

Authors:  M Stewart; C I Dovas; E Chatzinasiou; T N Athmaram; M Papanastassopoulou; O Papadopoulos; P Roy
Journal:  Vaccine       Date:  2012-01-26       Impact factor: 3.641

3.  Bluetongue virus: surface exposure of VP7.

Authors:  S A Lewis; M J Grubman
Journal:  Virus Res       Date:  1990-04       Impact factor: 3.303

4.  High level expression of the major core protein VP7 and the non-structural protein NS3 of bluetongue virus in yeast: use of expressed VP7 as a diagnostic, group-reactive antigen in a blocking ELISA.

Authors:  J C Martyn; A R Gould; B T Eaton
Journal:  Virus Res       Date:  1991-03       Impact factor: 3.303

5.  Mapping of two immunodominant antigenic epitopes conserved among the major inner capsid protein, VP7 of five bluetongue viruses.

Authors:  J K Li; Y Y Yang
Journal:  Virology       Date:  1990-10       Impact factor: 3.616

Review 6.  Structure of the bluetongue virus genome and its encoded proteins.

Authors:  P Roy; J J Marshall; T J French
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

Review 7.  Bluetongue virus genetics and genome structure.

Authors:  P Roy
Journal:  Virus Res       Date:  1989-07       Impact factor: 3.303

8.  Comparison of the standard AGID test and competitive ELISA for detecting bluetongue virus antibodies in camels in Gujarat, India.

Authors:  B S Chandel; H C Chauhan; H N Kher
Journal:  Trop Anim Health Prod       Date:  2003-04       Impact factor: 1.559

9.  A competitive ELISA for the detection of anti-tubule antibodies using a monoclonal antibody against bluetongue virus non-structural protein NS1.

Authors:  J Anderson; P P Mertens; K A Herniman
Journal:  J Virol Methods       Date:  1993-07       Impact factor: 2.014

10.  A single point mutation in the VP7 major core protein of bluetongue virus prevents the formation of core-like particles.

Authors:  H Le Blois; P Roy
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.